Werewolf Therapeutics obtains exclusive EMD license for WTX-124, WTX-330
Hammerstone MarketTalk reports that HOWL Werewolf Therapeutics obtains an exclusive license from EMD for the development of WTX-124 and WTX-330, as stated in an SEC filing.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.